Clinical guideline for the prevention and treatment of osteoporosis
Updated September 2021
Contents of the Clinical Guideline: NOGG 2021
Section 1
Section 4
Section 6
Section 7
Strategies for management of osteoporosis and fracture risk
- Duration and monitoring of bisphosphonate treatment
- Reassessment of fracture risk in individuals on osteoporosis drug treatment
- Rare adverse effects of long-term bisphosphonate and denosumab treatment
- Glucocorticoid-induced osteoporosis
- Men receiving androgen-deprivation therapy
- Women receiving aromatase inhibitor therapy
Section 9
Section 10
Appendix 1
Appendix 2
Appendix 3